Veracyte is trading 4.02% down at $44.19, with no clear company-specific catalyst identified for the October 1, 2026 decline. - Recent company news included trial findings and planned ASTRO presentations, but neither directly explains the drop. - Broader indices were little changed or higher. The move appears stock-specific, but available evidence does not establish a market-wide cause. - Reported volume was 622,427 shares at an earlier session snapshot; this is partial-session context, not final daily volume.